Ikshwaki Kaushik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ikshwaki Kaushik has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Abubakar Nazir
Department of Internal Medicine, The Jewish Hospital, Cincinnati, OH
2 shared publications - Jack Wellington
Department of Research and Education, Oli Health Magazine Organization, Kigali, Rwanda
2 shared publications - Olivier Uwishema
Department of Research and Education, Oli Health Magazine Organization, Kigali, Rwanda
2 shared publications - Abdulkadir Yusif Maigoro
Convergence Research Center for Insect Vectors, Incheon National University, Incheon 22012, Republic of Korea
1 shared publication - Abdulkarim Surajo Abdulkarim
Department of Medicine and Surgery, College of Health Sciences Bayero University Kano Kano State Nigeria
1 shared publication - Abdullahi Adeyemi Adegoke
Department of Pharmacognosy, University of Ibadan, Ibadan 200132, Nigeria
1 shared publication
Latest Publications
- Open Access
- 4 January 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (1) , e1797
Unlocking the potential of novel RTS, S/AS01, and R21/Matrix‐M™ malaria vaccines in African nations
Introduction: Mass malaria vaccination, rather than vaccinating only children below age 5, has been proven to have the potential to reduce morbidity and mortality among those vaccinated, both young and old. Addressing vaccine scepticism and misinformation is crucial in African nations to build public trust in malaria prevention. Therefore, including a wider range of demographics in vaccine trials is necessary for equitable representation and achieving herd immunity against malaria.Aim: This present article aims to identify some of the obstacles that impede malaria vaccination usage and acceptability in African Nations in combating malaria in the region as it continues to pose a significant global public health problem.Methodology: A literature search was done on the Malaria vaccine between 2000 and 2023. Past and present articles/studies on this topic were consulted on PubMed, Google Scholar, Scopus and Web of Science using the following keywords; “Malaria,” “Vaccines,” “African Nations,” “Obstacles, Strategies,” and “Public Health.”Results: The recently approved RTS, S/AS01, and R21/Matrix‐M™ Malaria vaccines have the potential to prevent numerous deaths and cases of Malaria in Africa. These vaccines Malaria vaccines are cost‐effective in African areas with moderate to high plasmodium falciparum and can be delivered through routine immunization.Conclusion: To combat malaria effectively in African Nations, African leaders need to set up a comprehensive approach that involves; prevention, healthcare access, implementation research strategies towards adoption and acceptance of malaria vaccines in Africa as well as community engagement with the religious leaders, the market women, community heads, schools, as well as students’ union towards the willingness and acceptability of the malaria vaccines among the African populations.
- 4 January 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (1) , e1797
Open AccessUnlocking the potential of novel RTS, S/AS01, and R21/Matrix‐M™ malaria vaccines in African nations
Introduction: Mass malaria vaccination, rather than vaccinating only children below age 5, has been proven to have the potential to reduce morbidity and mortality among those vaccinated, both young and old. Addressing vaccine scepticism and misinformation is crucial in African nations to build public trust in malaria prevention. Therefore, including a wider range of demographics in vaccine trials is necessary for equitable representation and achieving herd immunity against malaria.Aim: This present article aims to identify some of the obstacles that impede malaria vaccination usage and acceptability in African Nations in combating malaria in the region as it continues to pose a significant global public health problem.Methodology: A literature search was done on the Malaria vaccine between 2000 and 2023. Past and present articles/studies on this topic were consulted on PubMed, Google Scholar, Scopus and Web of Science using the following keywords; “Malaria,” “Vaccines,” “African Nations,” “Obstacles, Strategies,” and “Public Health.”Results: The recently approved RTS, S/AS01, and R21/Matrix‐M™ Malaria vaccines have the potential to prevent numerous deaths and cases of Malaria in Africa. These vaccines Malaria vaccines are cost‐effective in African areas with moderate to high plasmodium falciparum and can be delivered through routine immunization.Conclusion: To combat malaria effectively in African Nations, African leaders need to set up a comprehensive approach that involves; prevention, healthcare access, implementation research strategies towards adoption and acceptance of malaria vaccines in Africa as well as community engagement with the religious leaders, the market women, community heads, schools, as well as students’ union towards the willingness and acceptability of the malaria vaccines among the African populations.
- Open Access
- 7 September 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (11) , 5504-5510
Long-term cognitive dysfunction after the COVID-19 pandemic: a narrative review
Introduction: SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has brought a conglomerate of novel chronic disabling conditions described as ‘Long COVID/Post-COVID-19 Syndrome’. Recent evidence suggests that the multifaceted nature of this syndrome results in both pulmonary and extrapulmonary sequelae,chronic dyspnoea, persistent fatigue, and cognitive dysfunction being the most common, debilitating symptoms. Several mechanisms engender or exacerbate cognitive impairment, including central nervous system and extra-central nervous system causes, although the exact mechanism remains unclear. Both hospitalized and non-hospitalized patients may suffer varying degrees of cognitive impairment, ranging from fatigue and brain fog to prolonged deficits in memory and attention, detrimental to the quality-of-life years post-recovery. The aim of this review is to understand the underlying mechanisms, associations, and attempts for prevention with early intervention of long-term cognitive impairment post-COVID-19. Methodology: A systematic search was conducted through multiple databases such as Medline, National Library of Medicine, Ovid, Scopus database to retrieve all the articles on the long-term sequalae of cognitive dysfunction after SARS-CoV-2 infection. The inclusion criteria included all articles pertinent to this specific topic and exclusion criteria subtracted studies pertaining to other aetiologies of cognitive dysfunction. This search was carefully screened for duplicates and the relevant information was extracted and analysed. Results/discussion: To date, the exact pathogenesis, and underlying mechanisms behind cognitive dysfunction in COVID-19, remain unclear, hindering the development of adequate management strategies. However, the proposed mechanisms suggested by various studies include direct damage to the blood-brain barrier, systemic inflammation, prolonged hypoxia, and extended intensive care admissions. However, no clear-cut guidelines for management are apparent. Conclusion: This review of the COVID-19 pandemic has elucidated a new global challenge which is affecting individuals’ quality of life by inducing long-term impaired cognitive function. The authors have found that comprehensive evaluations and interventions are crucial to address the cognitive sequelae in all COVID-19 patients, especially in patients with pre-existing cognitive impairment. Nevertheless, the authors recommend further research for the development of relevant, timely neurocognitive assessments and treatment plans.
- 7 September 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (11) , 5504-5510
Open AccessLong-term cognitive dysfunction after the COVID-19 pandemic: a narrative review
Introduction: SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has brought a conglomerate of novel chronic disabling conditions described as ‘Long COVID/Post-COVID-19 Syndrome’. Recent evidence suggests that the multifaceted nature of this syndrome results in both pulmonary and extrapulmonary sequelae,chronic dyspnoea, persistent fatigue, and cognitive dysfunction being the most common, debilitating symptoms. Several mechanisms engender or exacerbate cognitive impairment, including central nervous system and extra-central nervous system causes, although the exact mechanism remains unclear. Both hospitalized and non-hospitalized patients may suffer varying degrees of cognitive impairment, ranging from fatigue and brain fog to prolonged deficits in memory and attention, detrimental to the quality-of-life years post-recovery. The aim of this review is to understand the underlying mechanisms, associations, and attempts for prevention with early intervention of long-term cognitive impairment post-COVID-19. Methodology: A systematic search was conducted through multiple databases such as Medline, National Library of Medicine, Ovid, Scopus database to retrieve all the articles on the long-term sequalae of cognitive dysfunction after SARS-CoV-2 infection. The inclusion criteria included all articles pertinent to this specific topic and exclusion criteria subtracted studies pertaining to other aetiologies of cognitive dysfunction. This search was carefully screened for duplicates and the relevant information was extracted and analysed. Results/discussion: To date, the exact pathogenesis, and underlying mechanisms behind cognitive dysfunction in COVID-19, remain unclear, hindering the development of adequate management strategies. However, the proposed mechanisms suggested by various studies include direct damage to the blood-brain barrier, systemic inflammation, prolonged hypoxia, and extended intensive care admissions. However, no clear-cut guidelines for management are apparent. Conclusion: This review of the COVID-19 pandemic has elucidated a new global challenge which is affecting individuals’ quality of life by inducing long-term impaired cognitive function. The authors have found that comprehensive evaluations and interventions are crucial to address the cognitive sequelae in all COVID-19 patients, especially in patients with pre-existing cognitive impairment. Nevertheless, the authors recommend further research for the development of relevant, timely neurocognitive assessments and treatment plans.
- Open Access
- 24 January 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (2) , 186-188
Addressing the challenges of prevention and control of West Nile virus in Africa: A correspondence
- 24 January 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (2) , 186-188
Open AccessAddressing the challenges of prevention and control of West Nile virus in Africa: A correspondence